Dr. Feldman on the Utility of PET Scan in Hodgkin Lymphoma

Video

In Partnership With:

Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.

Tatyana Feldman, MD, hematologist and medical oncologist, John Theurer Cancer Center, discusses the utility of PET scan in Hodgkin Lymphoma.

Patients with Hodgkin lymphoma may develop residual masses in the mediastinum, making it difficult to differentiate active disease from scar tissue with a CAT scan, says Feldman.

As such, patients were historically overtreated and radiation was commonly used, explains Feldman. Additionally, splenic disease was not often detected with CAT scan.

PET scan was a major advancement in this field, says Feldman. Moreover, the majority of patients who have negative PET scan results after 2 cycles of chemotherapy are considered cured.

Multiple randomized phase III trials have demonstrated the utility of PET scan, says Feldman. Patients with bulky disease or early-stage disease may be spared radiation therapy or receive deescalated chemotherapy based on PET scan results.

As there are some limitations to PET scan, circulating tumor DNA testing may provide an alternative modality to accurately evaluate complete responses versus progressive disease in patients with Hodgkin lymphoma.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS